BAF Subunit Biomarker Testing for Topoisomerase Inhibitor Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating cancer with topoisomerase inhibitors are ineffective due to the lack of selective targeting, leading to toxicity and secondary neoplasms, as they do not differentiate between cancer cells with functional BAF complexes and those with mutations, resulting in inadequate treatment response and side effects.
Innovation Solution
The method involves obtaining tumor and non-tumor samples to determine the activity of BAF subunits, specifically SMARCA4, ARID1A, and other BAF complex subunits, to assess the likelihood of topoisomerase inhibitor effectiveness, allowing for targeted treatment of cancer patients with functional BAF complexes while avoiding those with mutations that render them resistant.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topoisomerase inhibitors are used to treat cancer, then cancer cell death is achieved, but toxicity and secondary neoplasms occur due to lack of selective targeting
Solution Approach 1:
The patent applies local quality by identifying and targeting only cancer cells with functional BAF complexes using specific biomarkers (e.g., BRG1, BRM protein expression or DNA methylation patterns), thereby delivering topoisomerase inhibitors selectively to susceptible tumor cells while sparing normal cells, thus reducing toxicity and secondary neoplasms while maintaining treatment effectiveness
Solution Approach 2:
The patent uses biomarkers as intermediaries to mediate between the topoisomerase inhibitor and the cancer cell. These biomarkers (BAF complex subunit expressions or methylation patterns) serve as selective markers that guide the inhibitor to only those cancer cells with functional BAF complexes, preventing harmful effects on cells without the target marker
2Reliability
If genetic testing is performed to identify responsive patients, then treatment effectiveness is improved, but treatment costs increase
Solution Approach 1:
The patent changes the parameter for patient selection from complex multi-gene panels to specific, measurable biomarkers such as BRG1/BRM protein expression levels or specific DNA methylation patterns. These simplified parameters can be detected using cost-effective methods like immunohistochemistry or methylation-specific PCR, reducing testing costs while maintaining high accuracy in predicting treatment responsiveness
Data Source
AI summary
Methods for identifying and treating cancer patients likely to respond to topoisomerase inhibitors or likely to fail to respond to topoisomerase inhibitors are provided. The methods take advantage of the newly discovered role of BAF complexes in decatenation of DNA by topoisomerase IIa. Cancer cells are frequently at least partly defective in BAF complex activity. Such cells are targeted for therapy using certain topoisomerase IIa inhibitors according to the disclosed methods of treatment. Therapy of such cells using other topoisomerase inhibitors should be avoided.